Related Experiment Video
Updated: Jul 23, 2026
12:43
Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
Published on: July 27, 2016
Ryanodine receptor point mutant E4032A reveals an allosteric interaction with ryanodine
J D Fessenden1, L Chen, Y Wang
1Department of Molecular Biosciences, School of Veterinary Medicine, University of California, 1 Shields Avenue, Davis, CA 95616, USA.
Summary
Ryanodine receptor (RyR) studies reveal ryanodine binding allosterically alters RyR1 channel function, restoring activity in a mutant protein by inducing conformational changes, not pore blockage.
Area of Science:
- Molecular Biology
- Biophysics
- Cell Physiology
Background:
- Ryanodine receptors (RyRs) are calcium channels crucial for intracellular calcium release.
- Ryanodine is a tool used to study RyR function, with proposed mechanisms involving pore blockage.
- A specific RyR1 point mutant (E4032A) shows severely impaired channel activity.
Purpose of the Study:
- To investigate the effect of ryanodine on the E4032A RyR1 mutant.
- To determine the mechanism by which ryanodine influences RyR1 channel function.
- To explore if ryanodine binding directly blocks the RyR pore or induces allosteric changes.
Main Methods:
- Expression of RyR1 E4032A mutant in RyR-null myotubes.
- Stimulation assays using cell depolarization and RyR agonists.
- Single-channel electrophysiology recordings of E4032A channels with and without ryanodine.
- Analysis of channel gating properties and calcium sensitivity.
Main Results:
- Ryanodine treatment restored depolarization and agonist-induced responsiveness in E4032A-expressing myotubes.
- Restored E4032A channels exhibited Ca(2+)-dependent activity with multiple conductance substates upon ryanodine addition.
- Single-channel studies showed E4032A has poor gating and Ca(2+) insensitivity, which ryanodine normalized.
Conclusions:
- Ryanodine does not occlude the RyR pore but binds to allosteric sites.
- Ryanodine binding induces significant conformational changes in the RyR1 channel.
- These allosteric changes in RyR1 overcome the functional deficits caused by the E4032A mutation, restoring channel activity.
Related Concept Videos
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...